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Abstract Transforming growth factor-L (TGF-L) and bone
morphogenetic proteins (BMPs) signal via distinct type I and
type II receptors and Smad proteins. A nine amino acid sequence
between kinase subdomains IV and V in type I receptors, termed
the L45 loop, has been shown to be important in conferring
signalling specificity. We examined the responses of a mutant
TGF-L type I receptor (TLR-I) and a mutant BMPR-IB, in
which the L45 regions of these two receptors were exchanged.
Swapping the four amino acid residues that are different in
BMPR-IB for those in TLR-I, and vice versa, switched their type
I receptor-restricted Smad activation and specificity in transcrip-
tional responses. These studies identify the L45 loop regions in
type I receptors as critical determinants in specifying Smad
isoform activation.
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1. Introduction
Transforming growth factor-Ls (TGF-Ls), activins,
muºllerian inhibiting substance (MIS) and bone morphogenetic
proteins (BMPs) are structurally related proteins that control
a broad range of cellular processes, including proliferation,
di¡erentiation, apoptosis and migration. Although certain bio-
logical activities are shared between multiple ligands, each
ligand has also distinct biological responses [1^4]. Signalling
of these pleiotropic dimeric molecules occurs via ligand-in-
duced complex formation of two related serine/threonine ki-
nase receptors, i.e. type I and type II receptor [5^7]. Di¡erent
TGF-L family members bind distinct type II and type I re-
ceptors. Seven type I receptors, also termed activin receptor-
like kinases (ALKs) have been identi¢ed to date; ALK5 is a
TGF-L type I receptor (TLR-I), ALK2 and ALK4 are known
as activin type I receptor (ActR-I) and ActR-IB, respectively,
and ALK3 and ALK6 as BMP type IA receptor (BMPR-IA)
and BMPR-IB, respectively. The physiological ligands for
ALK1 and ALK7 are unknown [5^7]. Both receptors have
been shown to be essential for signalling. Type I receptors
act downstream of type II receptors; type I receptor kinases
become activated upon phosphorylation by the constitutively
active type II receptor kinase and propagate the signal down-
stream [8,9]. Consistent with these ¢ndings, type I receptors
were found to determine the speci¢city of the intracellular
signals induced by di¡erent TGF-L family members [10,11].
Using chimeric receptors of ALK2 and ALK5 the L45 region
was found to be important in determining the signalling spe-
ci¢city of type I receptors [12].
Members of the Smad family of proteins have been shown
to play a pivotal role in the intracellular signalling of TGF-L
family members [13^16]. The so-called pathway-restricted
Smads interact with and become phosphorylated by the type
I receptor kinases at two serine residues in their extreme C-
terminal ends [15,17^27], whereafter they form heteromeric
complexes with common-mediator Smad4 [22,28,29]. The het-
eromeric complex is then translocated to the nucleus
[15,17,20,24] and controls the transcription of target genes
[30]. Smad proteins have two regions of high sequence sim-
ilarity at their N- and C-terminal regions, termed Mad ho-
mology (MH)1 and MH2 domain, respectively. The N-termi-
nal region has been shown to have potential of direct sequence
speci¢c DNA binding activity [31^35], and the C-terminal
domain can act as a transcriptional activator [17,36].
Di¡erent pathway-restricted Smads couple with di¡erent
type I receptors and thus specify their responses; whereas
ALK5 interacts with Smad2 and Smad3, but not Smad1 or
Smad5. ALK6 binds to Smad1 and Smad5, but not Smad2 or
Smad3 [15,20^24,37,38]. In the present investigation we have
investigated whether exchanging the L45 loop regions between
ALK5 and ALK6 is su⁄cient to switch their speci¢city in
Smad activation and Smad-mediated transcriptional re-
sponses.
2. Materials and methods
2.1. Expression plasmids
Expression constructs for wild-type and constitutively active recep-
tors have been described [24]. ALK5BL45 and ALK6TL45 were made
by polymerase chain reaction (PCR)-mediated approach using a site-
directed mutagenesis kit (Stratagene) and subcloning in pCDNA3. To
obtain the constitutively active versions of ALK5BL45 and
ALK6TL45 the L45 regions were subcloned into the constitutively
active versions of ALK5 and ALK6, respectively. GAL4-Lux was
obtained from Johan Ericsson [39]. pSG424, pSG424Smad1(FL)
and pSG424Smad2(FL) have been described [17]. (CAGA)12MLP-
Luc, a multimerised response element derived from the PAI-1 pro-
moter and inducible by TGF-L, but not BMP, and (SBE)4-Lux, a
multimerised response element derived from the JunB promoter and
inducible by both TGF-L and BMP, have been described [34,35].
2.2. Antisera
For generation of antiserum PS2 recognising the phosphorylated C-
tail in Smad2, a peptide KKK-SSpMSp, containing two C-terminal
phosphoserine residues, was coupled to keyhole limpet hemocyanin
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(KLH) using glutaraldehyde, mixed with Freund’s adjuvant, and used
to immunise rabbits. In a similar manner PS1, recognising the phos-
phorylated C-tail in Smad1 was generated; a peptide KKK-NPISSVS,
containing two C-terminal phosphoserine residues was coupled to
KLH. The N-terminal lysine residues were added to facilitate coupling
to KLH. Speci¢city of the antiserum was tested after immunopreci-
pitation of metabolically labelled cell lysates from COS cells trans-
fected with Smads in the absence or presence of activated type I
receptors, as well as from non-transfected cells before and after stim-
ulation with TGF-L1 and BMP-7 (data not shown). Anti-Flag anti-
body was obtained from Kodak, and haemagglutinin (HA) antibody,
also termed YPY, was raised in rabbits against a peptide containing
two HA epitopes coupled to KLH.
2.3. Cell assays
Transfection of cells, metabolic labelling, immunoprecipitation, af-
¢nity cross-linking, and sodium dodecyl sulfate-polyacrylamide gel
electrophoresis were performed as described [24].
2.4. Transcriptional response assay
Mv1Lu cells lacking functional TLR-I (termed R-mutant) [40] were
transfected with reporter constructs using Superfect (Qiagen). In each
experiment, equal amounts of DNA were transfected. Luciferase ac-
tivity was measured as described [24], and normalised for transfection
e⁄ciency. Results shown are representative of at least three independ-
ent experiments.
3. Results and discussion
3.1. TLR-I/ALK5 and BMPR-IB/ALK6 with exchanged L45
loop regions
To determine whether the L45 loop can de¢ne receptor-
Smad interactions, we compared the ability of ALK5-re-
stricted Smads and ALK6-restricted Smads to interact with
mutants of ALK5 and ALK6, in which the L45 loops were
exchanged, termed ALK5BL45 and ALK6TL45, respectively.
Mutant receptors were made using a PCR-based approach.
The L45 loop in ALK5, ADNKDNGTW, di¡ers in four ami-
no acid residues from the L45 loop in ALK6, ADIKGTGSW
(Fig. 1). Both mutant receptors were found to bind ligand and
had an intrinsic kinase activity comparable to that of the wild-
type counterparts (data not shown).
3.2. Switching receptor-restricted Smad phosphorylation
Smad2 and Smad1 become phosphorylated upon interac-
tion with activated ALK5 and activated ALK6, respectively
[15,20^24,37,38]. We therefore compared the ability of ALK5,
ALK6, ALK6TL45 and ALK5BL45 to phosphorylate these
two Smads. COS cells were transfected with wild-type (wt) or
constitutively active (ca) HA-tagged type I receptors together
with Flag-tagged Smad2. The phosphorylation levels of
Smad2 were examined by 35S metabolic labelling followed
by immunoprecipitation of the cell lysates using PS2 antise-
rum that speci¢cally recognises the phosphorylated C-tail of
Smad2. As expected, constitutively active ALK5, but not con-
stitutively active ALK6, phosphorylated Smad2 at serine res-
idues in its C-tail. Interestingly, constitutively active
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Fig. 1. A: Amino acid sequence alignment of the L45 loops from
the type I receptors. The type I receptors are divided in three sub-
groups based upon their amino acid sequence similarities within the
L45 loop. Parts of the £anking kinase subdomains IV and V are
also shown. Amino acid residues that are conserved in more than 4
receptors are boxed. ALK-2, ALK3, ALK4, ALK5 and ALK6 are
also known as ActR-I, BMPR-IA, ActR-IB, TLR-I and BMPR-IB,
respectively. B: Schematic overview of ALK5BL45 and ALK6TL45.
Fig. 2. Smad phosphorylation by receptors. Comparison of wild-
type vs. constitutively active versions of ALK5 (TLR-I)-, ALK6
(BMPR-IB)-, ALK5BL45- and ALK6TL45-mediated phosphoryla-
tion of (A) Smad2 and (B) Smad1. Phosphorylation levels of Smad2
and Smad1 were examined on metabolically labeled cultures using
PS2 and PS1 antiserum, respectively. Expression of HA-tagged type
I receptors and Flag-tagged Smads were determined by immunopre-
cipitation with HA and Flag antiserum, respectively, of parallel cul-
tures which were metabolically labelled. wt, wild-type; ca, constitu-
tively active.
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ALK6TL45 gained ability to phosphorylate Smad2, whereas
constitutively active ALK5BL45 failed to phosphorylate
Smad2 (Fig. 2A). In an analogous manner the Smad1 phos-
phorylation by ALK5, ALK6, ALK6TL45 and ALK5BL45
was examined in transfected COS cells. The phosphorylation
levels of Smad1 were examined by 35S metabolic labelling
followed by immunoprecipitation of the cell lysates using
PS1 antiserum that speci¢cally recognises the phosphorylated
C-tail of Smad1. Constitutively active ALK5BL45, but not
constitutively active ALK5, phosphorylated Smad1, and the
level of Smad1 phosphorylation induced by ALK6TL45 was
much lower than by constitutively active ALK6 (Fig. 2B).
Thus, swapping the 4 di¡erent amino acid residues in L45
loop regions enabled ALK6 to phosphorylate Smad2 and
ALK5 to phosphorylate Smad1.
3.3. Switching receptor-restricted Smad transcriptional
activation
Smads were shown to have transcriptional activity; when
fused to GAL4 DNA binding domain, Smad1 and Smad2
activate a luciferase reporter containing GAL4 DNA binding
sites upon activation by BMP and TGF-L, respectively [17,36].
We assayed the ability of constitutively active derivatives of
ALK5, ALK6, ALK5BL45 or ALK6TL45 to activate GAL4-
Smad1- or GAL4-Smad2-mediated reporter activities in
Mv1Lu mink epithelial cells lacking functional ALK5, termed
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Fig. 4. Transcriptional e¡ects of receptors. Receptor constructs were transfected into R mutant cells together with (A) (CAGA)12MLP-Luc or
(B) (SBE)4-Lux reporters, and after stimulation with ligand luciferase activity was measured. In a similar way constitutively active and wild-
type receptor constructs were transfected into R-mutant cells together with (C) (CAGA)12MLP-Luc or (D) (SBE)4-Lux reporters, and luciferase
activity was measured. Data are the means þ S.D. of triplicate experiments.
Fig. 3. Stimulation of transcriptional activity of Smad1 and Smad2
by receptors. Empty pSG424 vector, (A) pSG424Smad1(FL) or (B)
pSG424Smad2(FL) constructs were transfected into R-mutant cells
together with constitutively active versions of ALK5, ALK6,
ALK5BL45 or ALK6TL45, and a GAL4-Lux reporter gene. Luci-
ferase activity was normalised for transfection e⁄ciency. Data are
the means þ S.D. of triplicate experiments.
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R-mutant cells (Fig. 3). We found that ALK5BL45 mimicked
ALK6 since both activated GAL4-Smad1. In addition, the
ability to activate GAL4-Smad1 by ALK6TL45 was much
weaker than that by ALK6. Moreover, ALK6TL45 and
ALK5 shared a similar ability to activate GAL4-Smad2.
However, ALK5BL45 was able to transcriptionally activate
Smad2, although less e⁄ciently than ALK5. Thus, swapping
of the L45 loop regions between ALK5 and ALK6 was su⁄-
cient to obtain a near to complete switch in their speci¢city of
Smad activation, indicating that the L45 loop structural motif
has a critical role in specifying which Smads become acti-
vated.
3.4. Switching receptor-restricted transcriptional responses
We have previously described a transcriptional reporter
(CAGA)12MLP-Luc containing response elements derived
from the PAI-1 promoter, which is inducible by TGF-L but
not BMPs [34]. In addition, we have shown that a transcrip-
tional (SBE)4-Lux reporter with response elements derived
from the JunB promoter, can be e⁄ciently induced by TGF-
L as well as BMPs [35]. Using these two reporter constructs
we analysed the ligand mediated transcriptional responses
upon activation with ALK5, ALK6, ALK5BL45 or
ALK6TL45 in R-mutant cells. In order to circumvent the
possibility of ligand induced signalling complexes with endog-
enous receptors we also analysed wild-type receptors vs. their
constitutively active counterparts (Fig. 4). The (CA-
GA)12MLP-Luc reporter was activated with ALK6TL45 as
well as with ALK5, whereas ALK5BL45 like ALK6 did not
activate this. As expected, all constructs activated the (SBE)4-
Lux reporter, which does not discriminate between ALK5-
and ALK6-induced responses. The reason for the relatively
high level of ligand-independent signalling activity of
ALK6TL45, and to a lesser extent ALK5BL45, compared
to their wild-type counterparts is unknown. Thus, exchanging
the L45 loop between ALK5 and ALK6 altered their ability
to activate transcriptional responses, in accordance with their
changed speci¢city in Smad isoform activation.
3.5. Concluding remarks
The L45 loop structural motif in type I receptors speci¢es
Smad isoform activation. Our results are consistent with a
recent report by Chen et al. [41]; they also ¢nd that L45
loop regions establish the speci¢city of receptor-Smad inter-
actions. The L45 loop regions of type I receptors can be
placed in three distinct subgroups (Fig. 1); ALK4, ALK5
and ALK7 have an identical L45 loop amino acid sequence,
as have ALK3 and ALK6, and there is only one amino acid
di¡erence between the L45 loops of ALK1 and ALK2 (Fig.
1). It is possible that the interactions of type I receptors within
one subgroup with di¡erent Smad proteins is similar.
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